MI

Mironid

4 known investors

mironid.com ↗

Mironid develops drug therapies targeting cAMP degrading phosphodiesterase enzymes for autosomal dominant polycystic kidney disease and other rare kidney diseases with significant unmet medical needs.

Investors · 4

EP

Epidarex CapitalBethesda · $2.5M – $6.3M

RO

Roche Venture FundBasel · $648K – $3.2M

SO

Sofinnova PartnersParis · $540K – $27M

BI

BioGeneration VenturesreportedNaarden